• Réf :HematoStat.net ; 2 (7) : V58 Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, […]

    Published On: 12 July 2022
  • Réf. :HematoStat.net ; 2 (7) : R53   Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Al-Sawaf O, Zhang C, Lu T, Liao […]

    Published On: 12 July 2022
  • Réf. :HematoStat.net ; 2 (7) : R52   Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized […]

    Published On: 12 July 2022
  • Réf :HematoStat.net ; 2 (4) : V51 Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, […]

    Published On: 27 April 2022
  • Published On: 14 March 2022
  • Réf :HematoStat.net ; 1 (12) : V36 Courtney D DiNardoand al.Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.  J Clin Oncol. […]

    Published On: 19 January 2022
  • Published On: 28 December 2021
  • Published On: 14 December 2021
  • Réf. :HematoStat.net ; 1 (1) : V7 Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak […]

    Published On: 10 June 2021